A fixed-dose combination topical preparation containing a potent corticosteroid (Mometasone furoate) and a bacteriostatic antibiotic (Fusidic acid). It is primarily indicated for the treatment of inflammatory dermatoses with secondary or suspected bacterial infection, particularly those caused by Staphylococcus aureus, including methicillin-resistant strains (MRSA). The combination provides anti-inflammatory, anti-pruritic, and antibacterial actions.
Adult: Apply a thin film to the affected area once daily. Duration should be limited, typically 1-2 weeks. Do not exceed 50g per week.
Note: 1. Wash and dry hands and affected area. 2. Apply a thin layer and rub gently until it disappears. 3. Do not cover with occlusive dressings unless specifically directed by a physician. 4. Avoid contact with eyes, mouth, nose, and mucous membranes. 5. Wash hands after application unless hands are the treated area.
Mometasone furoate binds to cytoplasmic glucocorticoid receptors, forming a complex that translocates to the nucleus. It modulates gene transcription, leading to the synthesis of anti-inflammatory proteins (lipocortin) and inhibition of pro-inflammatory mediators (cytokines, leukotrienes, prostaglandins). Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G (EF-G) and preventing the translocation step on the ribosome, leading to bacteriostatic action.
Pregnancy: Category C (US FDA). Topical corticosteroids, including mometasone, can be absorbed in amounts sufficient to produce systemic effects. Animal studies show teratogenicity. Use only if potential benefit justifies potential risk to the fetus. Avoid large amounts or long-term use.
Driving: No effect on ability to drive or operate machinery.
| Other Topical Corticosteroids | Additive risk of local and systemic side effects, including skin atrophy and HPA suppression. | Major |
| Live Vaccines (e.g., BCG, MMR, Varicella) | Systemic immunosuppression from absorbed steroid may potentiate replication of vaccine virus, leading to infection. | Major |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | May inhibit the metabolism of systemically absorbed mometasone, increasing the risk of systemic corticosteroid effects. | Moderate |